Approval · Notice of Compliance 10955 · 2010
GD-ELETRIPTAN: Notice of Compliance 10955
Issued January 26, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10955
- Date
- January 26, 2010
- Company
- Genmed A Division Of Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- 5-HT1 receptor agonist / Migraine therapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GD-ELETRIPTAN | 02342235 | Marketed |
| GD-ELETRIPTAN | 02342243 | Marketed |
Medicinal ingredients
- ELETRIPTAN HYDROBROMIDE 20 MG per TAB
- ELETRIPTAN HYDROBROMIDE 40 MG per TAB